Benzinga  Jun 22  Comment 
Compugen Ltd. (NASDAQ: CGEN) announced disclosed COM701 as the lead monoclonal antibody therapeutic candidate for its CGEN-15029 target program. The company made the announcement at the JMP Securities Life Science Conference in New...
Benzinga  Apr 18  Comment 
Compugen Ltd. (NASDAQ: CGEN) announced on Monday it has achieved a first preclinical milestone for CGEN-15022 as part of a cancer immunotherapy agreement with Bayer. The companies entered into a collaboration and license agreement in 2013 for...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki